– Newly formed Erase T2D task force comprises leading scientists and pioneering scientific research to elucidate the role of the duodenum in type 2 diabetes and metabolic control
– Fractyl Health-supported research projects are now underway at Vanderbilt University and University of Michigan
LEXINGTON, Mass., November 02, 2022–(BUSINESS WIRE)–Fractyl Health, an organ-editing metabolic therapeutics company focused on pioneering a new approach to the treatment of type 2 diabetes (T2D), announced the creation of the Erase T2D task force, an academic-industry scientific partnership charged with advancing research on the role of the gut in metabolic disease to catalyze future discoveries that may inform how type 2 diabetes (T2D) can be better understood and hopefully ‘erased.’ Fractyl Health further announces that this partnership’s first two research projects have now been initiated with Professor Alan Cherrington at Vanderbilt University and Professor Randy Seeley at University of Michigan. These two scientific research initiatives will establish a foundation of new evidence on nutrient sensing and signaling mechanisms in a segment of the intestine called the duodenum. The ambition is that this collaboration will lead to a deeper understanding of the possible causal relationship between a dysfunctional duodenum and the onset and progression of T2D.
The first of these studies, led by Alan Cherrington, Ph.D., Professor of Molecular Physiology & Biophysics, Professor of Medicine, and the Jacquelyn A. Turner and Dr. Dorothy J Turner Chair in Diabetes Research at Vanderbilt University School of Medicine, will focus on defining the gut-derived signaling pathways central to the development and progression of T2D. From Dr. Cherrington, "If the development of duodenal dysfunction as a consequence of high fat and sugar diets is an important event in the development of T2D, we need to try to understand which duodenal changes could represent key causal steps in metabolic dysregulation and diabetes pathogenesis."
The second study, led by Randy Seeley, Ph.D., Professor of Surgery and Director of Michigan Nutrition Obesity Research Center at the Elisabeth Weiser Caswell Diabetes Institute in the University of Michigan Medical School, will focus on establishing a rodent model of duodenal mucosal disruption to help better define the mechanism of action of therapies targeting the duodenal mucosa. "I am confident that we are taking the first steps in gaining a deeper understanding of the processes in the gut that lead to metabolic disease. This will enable us to identify precursors and therefore ultimately build increasingly effective therapeutic approaches that could lead to a metabolic reset in patients with T2D," notes Dr. Seeley.
These two studies will build upon a growing body of evidence by scientists around the world who have identified duodenal dysfunction as a potential root cause of metabolic disease (Aliluev et al; Duca et al). In spearheading this partnership, Fractyl Health is enthusiastic to begin this effort with academic partners who are icons in the field. "Our ambition is to support the deep science that will lead to a greater understanding of the root causes of T2D. We know these studies are the beginning of a journey and will lead to findings – and more questions – we can use to define our next steps in the process of discovery," says Harith Rajagopalan, M.D., Ph.D., Co-Founder and CEO of Fractyl Health.
About the Erase Task Force
The Erase Task Force is an academic-industry scientific partnership built on decades of scientific investigation which has identified the critical role of the gut as a regulator of metabolic disease. The signaling mechanisms between the gut and the rest of the body are numerous and not yet fully delineated. The Erase Task Force is charged with advancing research to catalyze future discoveries that may inform how T2D can be better understood and ultimately erased. Partnership members include: Alan Cherrington, Ph.D. (co-chair), Professor of Molecular Physiology & Biophysics, Professor of Medicine, and the Jacquelyn A. Turner and Dr. Dorothy J Turner Chair in Diabetes Research at Vanderbilt University School of Medicine; Harith Rajagopalan, M.D., Ph.D. (co-chair), Co-founder and CEO of Fractyl Health; Dave D’Alessio, M.D., Professor of Medicine and Chief of Division of Endocrinology and Metabolism at Duke University School of Medicine; Geltrude Mingrone, M.D., Ph.D., Professor of Diabetes and Nutrition at King’s College, London, Associate Professor of Internal Medicine at Catholic University of Rome; Randy Seeley, Ph.D., Professor of Surgery and Director of the Michigan Nutrition Obesity Research Center at University of Michigan Medical School.
About Fractyl Health
Fractyl Health is focused on pioneering a new approach to the treatment of T2D. Despite advances in treatment over the last 50 years, metabolic diseases in general, and T2D in particular, continue to be principal and rapidly growing drivers of morbidity and mortality in the 21st century. Fractyl Health’s goal is to transform T2D treatment from chronic blood glucose management to disease-modifying therapies that target the organ-level root causes of the disease. Fractyl Health is a private organ-editing metabolic therapeutics company based in Lexington, MA. For more information, visit www.fractyl.com or www.twitter.com/FractylHealth.
About Revita®
Fractyl Health’s lead product candidate, Revita, is based on the company’s insights surrounding the potential role of the gut in metabolic diseases. Revita is designed to remodel the duodenal lining via hydrothermal ablation (i.e., duodenal mucosal resurfacing) to edit abnormal intestinal nutrient sensing and signaling mechanisms that are a potential root cause of metabolic diseases. In April 2016, Revita received a CE mark from the European Union. In the United States, Revita is for investigational use only and has received Breakthrough Device designation from the FDA to improve glycemic control and eliminate insulin needs in T2D patients who are inadequately controlled on long-acting insulin.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221102005262/en/
Lisa Davidson, Chief Financial Officer
Lisa@fractyl.com, 781.902.8800
Nancye Green, Head of Corporate Communications
Ngreen@fractyl.com, 781.902.8800
G1 Therapeutics Inc (NASDAQ: GTHX) described safety data from the first 18 patients enrolled in its ongoing Phase 2 study of trilaciclib administered before sacituzumab govitecan-hziy in patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC). Sacituzumab govitecan is marketed as trodelvy by Gilead Sciences Inc (NASDAQ: GILD). "We believe we are seeing on-target effects of trilaciclib in the expected reduction in the rate of myelosuppression and the rates o
Surface Oncology Inc (NASDAQ: SURF) observed confirmed partial responses from SRF388 monotherapy data in non-small cell lung cancer (NSCLC) patients. The partial responses were observed in patients treated at or above the recommended Phase 2 dose (22% ORR (2/9)), which includes 100% (2/2) of patients with squamous NSCLC. Additionally, a patient with adenocarcinoma has experienced durable disease stabilization, ongoing for more than 56 weeks. Surface has initiated a single-arm Phase 2 study evalu
Yahoo Finance's Anjalee Khemlani breaks down CVS third-quarter earnings, the impact from an opioid lawsuit, and the growth in pharmacy and health care services.
President and CEO Michael Morrissey said the deals tap the company's balance sheet and share risks with its partners.
By John Vandermosten, CFA NASDAQ:BLRX READ THE FULL BLRX RESEARCH REPORT Commercialization Plans for Motixafortide (APHEXDA®) BioLineRx Ltd. (NASDAQ:BLRX) submitted its New Drug Application (NDA) to the FDA on September 9, 2022 for Motixafortide (now branded Aphexda) in stem cell mobilization for multiple myeloma patients undergoing autologous bone marrow transplantation. Since then, BioLineRx
J&J wanted a deal to boost its medical-device division, which will become more important after the company sheds its consumer-health business.
The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
When it comes to Medicare, understanding your healthcare needs and finding the right coverage are essential. But as you get close to or enter retirement, making decisions about your health can be overwhelming. To make the process a little easier, Vanguard … Continue reading → The post Vanguard's 3 Steps to Maximizing Your Medicare Coverage appeared first on SmartAsset Blog.
Mounjaro, the brand-new Type 2 diabetes therapy, brought in $187.3 million in sales in its first full quarter on the market
Inflation is 8.3%, medical costs are up by 5.4%, the average hospital stay for Medicare patients is $13,600 and the most recent estimate is that people aged 65 will pay $315,000 for medical care during their retirement years. So what's … Continue reading → The post Here's Why Retirees Can Breathe a Sigh of Relief appeared first on SmartAsset Blog.
When Claudia Siegel got a stomach bug this year, she contacted her primary care physician to get something to relieve her diarrhea. The Philadelphia resident was surprised when she received an online message informing her that because she hadn't visited her physician in more than three years, she was no longer a patient. And since he wasn't accepting new patients, she would have to find a new primary care physician.Subscribe to The Post Most newsletter for the most important and interesting stor
"The labor market has been a challenge," Jack Hartung says.
The Arizona GOP gubernatorial candidate criticized the late Sen. John McCain (R-Ariz.) for blocking Republican efforts to undo the health care law.
California is now an “emerging hotspot” for the family of variants, known to be the most immune evasive and transmissible yet, according to experts.
Walking can help you burn calories to lose weight. Here, experts share the number of calories burned walking and how to begin a walking plan.
(Reuters) -CVS Health Corp, Walgreens Boots Alliance Inc and Walmart Inc agreed to pay about $13.8 billion to resolve thousands of U.S. state and local lawsuits accusing the pharmacy chains of mishandling opioid pain drugs, potentially bringing years of litigation close to the finish line. CVS said on Wednesday it had agreed to pay about $5 billion over 10 years, and Walgreens said that it had agreed to pay about $5.7 billion over 15 years. Walmart has agreed to pay $3.1 billion, mostly up front, according to two people familiar with the matter.
Is Pfizer stock a buy or a sell as it aims to gain the first approval for a maternal SRV shot? Is PFE stock a buy or a sell right now?
The drug company raised its revenue projection for the year despite reporting a drop in third-quarter sales from a decline in Covid-19 vaccine sales outside the U.S.
Novo Nordisk raised its full-year earnings outlook after better-than-expected profit on strong sales of diabetes treatment Ozempic.
Hospitalizations are rising again in New York City with the spread of new COVID-19 subvariants that are better at evading immunity, along with flu and respiratory syncytial virus, or RSV.


By admin

Leave a Reply

Your email address will not be published. Required fields are marked *